Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment (LOCATE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02680041
Recruitment Status : Completed
First Posted : February 11, 2016
Results First Posted : January 28, 2019
Last Update Posted : January 28, 2019
Sponsor:
Collaborators:
American College of Radiology
IND 2 Results LLC
Syne Qua Non Limited
Information provided by (Responsible Party):
Blue Earth Diagnostics

Brief Summary:
This prospective study will enroll up to 330 men with PSA-persistent or PSA-recurrent prostate cancer after curative-intent primary therapy and negative or equivocal findings on standard-of-care imaging. Consenting participants will be imaged with 18F-fluciclovine PET/CT. Site clinicians will manage study subjects per standard practices and will document any change in treatment based on review of 18F-fluciclovine PET/CT findings. All participants will be followed for up to 6 months, with clinical data collected for this study. An interdisciplinary panel will provide expert guidance to local readers on request. The final reporting of the PET/CT scan will be a single report by the local reader following any such discussion.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: 18F-fluciclovine PET CT Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 221 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: The Impact of 18F Fluciclovine (FACBC) PET/CT (Positron Emission Computed Tomography) on Management of Patients With Rising PSA (Prostate-specific Antigen) After Initial Prostate Cancer Treatment
Actual Study Start Date : June 1, 2016
Actual Primary Completion Date : November 1, 2017
Actual Study Completion Date : November 1, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: 18F-fluciclovine PET CT
Single intravenous administration of 18F-fluciclovine PET CT.
Drug: 18F-fluciclovine PET CT
Subjects will undergo a fluciclovine F18 PET/CT scan in addition to standard of care monitoring. The results of this scan may influence further treatment
Other Name: FACBC




Primary Outcome Measures :
  1. The Fraction of Patients for Whom 18F-fluciclovine PET/CT Alters Patient Planned Treatment Through Detection of Disease. [ Time Frame: 2-22 days post PET CT ]
    The change of management will be based on referring physician questionnaires completed pre- and post- 18F-fluciclovine PET/CT


Secondary Outcome Measures :
  1. The Fraction of Patients for Whom 18F-fluciclovine PET/CT Alters Patient Actual Treatment [ Time Frame: 6 months ]

    The change of management will be based on referring physician questionnaires completed pre- 18F-fluciclovine PET/CT and changes reported at 6 month follow-up.

    Investigators were instructed to assess any clinically significant change from the revised management plan.


  2. The Rate of Detection of Any Disease Site by 18F-fluciclovine PET/CT in the Study Population [ Time Frame: 1 week ]
    The percentage of subjects who have disease detectable by 18F-fluciclovine PET/CT

  3. The Rate of Detection of Disease in 1) Prostate and Prostate Bed and 2) Extra-prostatic Regions With 18F-fluciclovine PET/CT in the Study Population [ Time Frame: 1 week ]
    The percentage of subjects who have disease detectable by 18F-fluciclovine PET/CT 1) in the pelvis and 2) distally

  4. The Positive Predictive Value (PPV) of 18F-fluciclovine PET/CT for Regional Disease Compared to Biopsy in Those Patients Who Undergo Biopsy or in Case of Bony Disease a Correlation With MRI or Biopsy [ Time Frame: 6 months ]
    Based on the ratio of positive findings in the pelvis on 18F-fluciclovine PET/CT which are confirmed by histological examination of tissue or MRI

  5. The PPV of 18F-fluciclovine PET/CT for Distant Disease Compared to Biopsy in Those Patients Who Undergo a Biopsy or in Case of Bony Disease a Correlation With MRI or Biopsy [ Time Frame: 6 months ]
    Based on the ratio of positive findings outside the pelvis on 18F-fluciclovine PET/CT which are confirmed by histological examination of tissue or MRI



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • History of histologically confirmed adenocarcinoma of the prostate post curative-intent local treatment (radical prostatectomy, local radiotherapy, brachytherapy).
  • Suspicion of recurrent prostate carcinoma after previous presumed definitive therapy for organ confined disease defined as :
  • Post prostatectomy: Detectable or rising PSA level that is >0.2 ng/mL with a second confirmatory level of >0.2 ng/mL
  • Post non-prostatectomy: PSA rise ≥ 2ng/mL over nadir
  • Negative or equivocal findings on standard-of-care imaging for restaging of disease in the previous 60 days consisting of: Whole-body 99mTc bone scintigraphy or NaF PET-CT; and either CT or MRI of the pelvis (or the abdomen and pelvis).
  • Being considered for salvage therapy
  • Any non-surgical local treatment such as previous cryotherapy, external beam radiation, or HiFU (Ultrasound) must have occurred at least 1 year in the past.
  • Previous brachytherapy treatment will have occurred at least 2 years in the past
  • Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

  • Ongoing treatment with any systemic therapy intended for the treatment of prostate cancer (e.g., antiandrogen or LHRH agonist or antagonist)
  • Androgen deprivation therapy (ADT) in the past 3 months
  • History of bilateral orchidectomy
  • Inability to tolerate 18F-fluciclovine PET/CT

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02680041


Locations
Layout table for location information
United States, California
City of Hope National Medical Center
Duarte, California, United States, 91010
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
Tower Urology
Los Angeles, California, United States, 90048
Genesis Research, LLC
San Diego, California, United States, 92123
United States, Florida
University of Florida
Jacksonville, Florida, United States, 32209
United States, Illinois
Loyola University Medical Center
Maywood, Illinois, United States, 60153
United States, Indiana
Roudebush VA Medical Center
Indianapolis, Indiana, United States, 46202
United States, Kentucky
University of Louisville
Louisville, Kentucky, United States, 40202
United States, Missouri
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
United States, New Jersey
Coastal Urology Associates
Brick, New Jersey, United States, 08724
United States, New York
Manhattan Medical Research
New York, New York, United States, 10016
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
United States, Pennsylvania
Urologic Consultants of SE Pennsylvania
Bala-Cynwyd, Pennsylvania, United States, 19004
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States, 19107
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
United States, Utah
University of Utah, Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112
Sponsors and Collaborators
Blue Earth Diagnostics
American College of Radiology
IND 2 Results LLC
Syne Qua Non Limited
Investigators
Layout table for investigator information
Study Chair: Umar Mahmood, MD, PhD Harvard Medical School
Study Director: Peter Gardiner, MB ChB, MRCP, FFPM Blue Earth Diagnostics
  Study Documents (Full-Text)

Documents provided by Blue Earth Diagnostics:
Study Protocol  [PDF] June 7, 2017
Statistical Analysis Plan  [PDF] March 5, 2018


Layout table for additonal information
Responsible Party: Blue Earth Diagnostics
ClinicalTrials.gov Identifier: NCT02680041     History of Changes
Other Study ID Numbers: BED003
First Posted: February 11, 2016    Key Record Dates
Results First Posted: January 28, 2019
Last Update Posted: January 28, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases